[go: up one dir, main page]

UA84896C2 - Производные гидронопола как агонисты человеческих рецепторов orl1 - Google Patents

Производные гидронопола как агонисты человеческих рецепторов orl1

Info

Publication number
UA84896C2
UA84896C2 UAA200607374A UAA200607374A UA84896C2 UA 84896 C2 UA84896 C2 UA 84896C2 UA A200607374 A UAA200607374 A UA A200607374A UA A200607374 A UAA200607374 A UA A200607374A UA 84896 C2 UA84896 C2 UA 84896C2
Authority
UA
Ukraine
Prior art keywords
agonists
receptors
hydronopol
derivatives
relates
Prior art date
Application number
UAA200607374A
Other languages
English (en)
Ukrainian (uk)
Inventor
Матиас Менцель
Даниа Б. Райхе
Райнхард Брюкнер
Самуэль Давид
Стин Бартоломеус Й. ван
Уве Шон
Даниэль Жассеран
Ульф Пройшофф
Original Assignee
Сольве Фармасьютикалз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сольве Фармасьютикалз Гмбх filed Critical Сольве Фармасьютикалз Гмбх
Publication of UA84896C2 publication Critical patent/UA84896C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретение касается группы производных гидронопола, которые являются агонистами человеческих рецепторов ORL1 (ноцицептина).Изобретение также касается способов получения этих соединений, фармацевтических композиций, которые содержат фармакологически активное количество, по крайней мере, одного из этих новых производных гидронопола как действующего вещества, а также применения этих фармацевтических композиций для лечения расстройств, связанных с рецепторами ORL1.Изобретение касается соединений общей формулы (1),где радикалы имеют значения, которые приведены в описании.
UAA200607374A 2003-12-12 2004-12-09 Производные гидронопола как агонисты человеческих рецепторов orl1 UA84896C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03104662 2003-12-12

Publications (1)

Publication Number Publication Date
UA84896C2 true UA84896C2 (ru) 2008-12-10

Family

ID=34924140

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200607374A UA84896C2 (ru) 2003-12-12 2004-12-09 Производные гидронопола как агонисты человеческих рецепторов orl1

Country Status (14)

Country Link
US (1) US7241770B2 (ru)
EP (1) EP1694675A2 (ru)
JP (1) JP2007513922A (ru)
CN (1) CN1890238A (ru)
AR (1) AR046756A1 (ru)
AU (1) AU2004298436A1 (ru)
BR (1) BRPI0417161A (ru)
CA (1) CA2547633A1 (ru)
MX (1) MXPA06005675A (ru)
RU (1) RU2351600C2 (ru)
TW (1) TW200522949A (ru)
UA (1) UA84896C2 (ru)
WO (1) WO2005058890A2 (ru)
ZA (1) ZA200604791B (ru)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045843A1 (es) * 2003-10-03 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolonas y quinazolinonas sustituidas con hidronopol como agonistas en receptores orl 1 humanos
WO2007067504A2 (en) 2005-12-05 2007-06-14 Incyte Corporation Lactam compounds and methods of using the same
EP2035420A2 (en) * 2006-06-20 2009-03-18 Wyeth a Corporation of the State of Delaware Kv1.5 potassium channel inhibitors
RU2458902C1 (ru) * 2011-07-08 2012-08-20 Учреждение Российской академии наук Институт катализа им. Г.К. Борескова Сибирского отделения РАН Способ получения миртанола
WO2014102590A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
US9951038B2 (en) 2012-12-27 2018-04-24 Purdue Pharma L.P. Quinazolin-4(3H)-one-type piperidine compounds and uses thereof
US9040533B2 (en) 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
US9963458B2 (en) 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
CN105531252B (zh) 2013-09-12 2018-01-09 信越化学工业株式会社 用于制备β‑环薰衣草醛及其衍生物的方法
WO2015037664A1 (ja) * 2013-09-12 2015-03-19 信越化学工業株式会社 シクロラバンジュロール及びその誘導体の製造方法
CN104557653A (zh) * 2014-12-31 2015-04-29 大连联化化学有限公司 7-甲基-氮杂-二环[4,1,0]庚烷的制备方法
BR112018000041A2 (pt) 2015-07-31 2018-09-04 Pfizer Inc. Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
KR102781748B1 (ko) 2015-12-02 2025-03-13 아스트레아 테라퓨틱스 엘엘씨 피페리디닐 노시셉틴 수용체 화합물
IL291323B2 (en) 2016-07-15 2023-09-01 Am Chemicals Llc Solid non-nucleoside supports and phosphoramidite building blocks for oligonucleotide synthesis
SG11201906417RA (en) 2017-01-20 2019-08-27 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
SG11201906427QA (en) 2017-01-23 2019-08-27 Pfizer Heterocyclic spiro compounds as magl inhibitors
IT201800007580A1 (it) * 2018-07-27 2020-01-27 Maria Cecilia Hospital Spa Composti 1,3,8-triazaspiro e loro uso come medicamenti
CN116410143A (zh) * 2021-12-29 2023-07-11 杭州奥默医药股份有限公司 一种多取代脲嘧啶衍生物及其制备方法和应用
CN115124441B (zh) * 2022-06-30 2024-04-02 南京林业大学 一类诺卜酸酰肼类化合物的制备方法和产品及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
DE69923744T2 (de) * 1998-10-23 2006-02-23 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten
JP2000169476A (ja) 1998-12-09 2000-06-20 Banyu Pharmaceut Co Ltd ４−オキソイミダゾリジン−５−スピロ−含窒素複素環式化合物
NZ516782A (en) * 1999-07-28 2004-12-24 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders
AU1948601A (en) * 1999-12-06 2001-06-12 Euro-Celtique S.A. Triazospiro compounds having nociceptin receptor affinity
US6777421B2 (en) * 2001-04-10 2004-08-17 Ortho-Mcneil Pharmaceutical, Inc. 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
MXPA05002622A (es) 2002-09-09 2005-09-08 Johnson & Johnson Derivados de 1,3,8,-triazaespiro [4.5]decan-4-ona sustituidos con hidroxialquilo utiles para el tratamiento de desordenes mediados por el receptor opioide huerfano.

Also Published As

Publication number Publication date
MXPA06005675A (es) 2006-08-17
TW200522949A (en) 2005-07-16
AR046756A1 (es) 2005-12-21
US7241770B2 (en) 2007-07-10
CN1890238A (zh) 2007-01-03
WO2005058890A2 (en) 2005-06-30
CA2547633A1 (en) 2005-06-30
AU2004298436A1 (en) 2005-06-30
ZA200604791B (en) 2008-07-30
RU2006124856A (ru) 2008-01-20
EP1694675A2 (en) 2006-08-30
JP2007513922A (ja) 2007-05-31
RU2351600C2 (ru) 2009-04-10
WO2005058890A3 (en) 2005-08-18
BRPI0417161A (pt) 2007-03-06
US20050131004A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
TW200517388A (en) Thiazole derivatives as cannabinoid receptor modulators
SE0302760D0 (sv) New compounds
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
IL157254A0 (en) N-substituted nonaryl-heterocyclic nmda/mr2b antagonists
MXPA05010859A (es) Antagonistas mchr1 heterociclicos.
SI1506185T1 (sl) Spojine in njihova uporaba kot inhibitorji 5-HT
WO2006011050A3 (en) Pyridine derivatives
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
PL370292A1 (en) Formulations for oral administration of active compounds
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
PT1696905E (pt) 2-aminotetralinas substituídas para o tratamento preventivo da doença de parkinson
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
WO2005060959A8 (en) Pyrazole derivatives and use thereof as orexin receptor antagonists
IL176546A0 (en) Imidazoline derivatives having cb1-antagonistic activity
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
EP2202222A3 (en) Indene derivatives, their preparation and use as medicaments
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
TW200514785A (en) Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
NO20063138L (no) Hydronopolderivater som agonister i human ORL1 receptorer
MX2007005824A (es) Agonistas y antagonistas del receptor de somatostatina.
NO20061966L (no) Bicyklo[3.1.1.]heptansubstituerte benzimidazolon- og kinazolinonderivater som agonister for humane ORL1 reseptorer
NO20061836L (no) Heksa- og oktahydro-pyndo[1,2-a]pyrazinderlvater med NK1 antagonistisk aktivitet